SeaSpine (NASDAQ:SPNE) Downgraded by StockNews.com to Sell

StockNews.com lowered shares of SeaSpine (NASDAQ:SPNEGet Rating) from a hold rating to a sell rating in a report released on Friday morning.

Several other brokerages also recently issued reports on SPNE. Piper Sandler decreased their target price on SeaSpine from $28.00 to $21.00 and set an overweight rating on the stock in a research note on Monday, March 14th. Cantor Fitzgerald decreased their target price on SeaSpine from $27.00 to $21.00 and set an overweight rating on the stock in a research note on Friday, April 22nd. Finally, Stifel Nicolaus decreased their target price on SeaSpine from $18.00 to $16.00 and set a buy rating on the stock in a research note on Monday, March 14th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, SeaSpine currently has an average rating of Buy and a consensus price target of $33.50.

NASDAQ SPNE opened at $6.72 on Friday. The stock’s 50-day moving average price is $8.78 and its 200-day moving average price is $11.10. SeaSpine has a 52 week low of $6.49 and a 52 week high of $21.98. The company has a market capitalization of $247.30 million, a P/E ratio of -4.17 and a beta of 1.29.

SeaSpine (NASDAQ:SPNEGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The medical equipment provider reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.09). The company had revenue of $50.69 million during the quarter, compared to the consensus estimate of $48.96 million. SeaSpine had a negative return on equity of 20.19% and a negative net margin of 29.09%. The firm’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period last year, the business earned ($0.46) EPS. On average, analysts forecast that SeaSpine will post -1.36 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. Citigroup Inc. increased its position in shares of SeaSpine by 135.5% during the 3rd quarter. Citigroup Inc. now owns 3,561 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 2,049 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of SeaSpine by 430.6% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 6,065 shares of the medical equipment provider’s stock valued at $95,000 after purchasing an additional 4,922 shares during the last quarter. Tradition Wealth Management LLC increased its position in shares of SeaSpine by 77.8% during the 1st quarter. Tradition Wealth Management LLC now owns 8,000 shares of the medical equipment provider’s stock valued at $97,000 after purchasing an additional 3,500 shares during the last quarter. Engineers Gate Manager LP bought a new position in shares of SeaSpine during the 1st quarter valued at approximately $137,000. Finally, Susquehanna International Group LLP bought a new position in shares of SeaSpine during the 4th quarter valued at approximately $163,000. 73.10% of the stock is currently owned by institutional investors and hedge funds.

SeaSpine Company Profile (Get Rating)

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine.

Further Reading

Analyst Recommendations for SeaSpine (NASDAQ:SPNE)

Want More Great Investing Ideas?

Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.